As well as correctors designed to right defects in CFTR protein expression.

The collaboration marks AbbVie’s second with Galapagos. The first partnership focuses on developing GLPG0634, a selective JAK1 inhibitor, against rheumatoid arthritis . It had been expanded in May to include Crohn’s disease. AbbVie agreed to pay Galapagos $50 million upon effective completion of a Stage IIa/b study, place to launch early next 12 months and generate topline results in Q2 2015, the firms said at that time. Galapagos acquired privileges to GLPG0634 from GlaxoSmithKline after an arthritis alliance with that ongoing organization ended.Adolor initiates ADL5945 Phase 2 proof-of-concept research for patients with OIC Adolor Corporation today announced the initiation of a Phase 2 proof-of-concept research of ADL5945 in patients suffering from opioid-induced constipation . Dougherty, President and Chief Executive Officer. We begin this study having just completed a single-ascending dose study of ADL5945 in healthful volunteers and a multiple-ascending dose research in OIC patients with chronic non-cancer pain.